Hematologic Oncology

Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

The FDA has accepted a supplemental new drug application for dasatinib (Sprycel) for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML).

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

The FDA has approved ClearLLab multicolor reagents (T1, T2, B1, B2, M) for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.

Jia Ruan, MD, PhD, discusses some of the ongoing work in the field of T-cell lymphoma and the unanswered questions investigators are still facing for these patients

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

Frontline brentuximab vedotin (Adcetris) was associated with improved progression-free survival compared with standard chemotherapy in patients with advanced classical Hodgkin lymphoma, according to results from the phase III ECHELON-1 clinical trial.

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.

Jorge E. Cortes, MD, discusses ongoing advances with FLT3 inhibitors in acute myeloid leukemia.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses molecular testing for patients with myelodysplastic syndromes (MDS).

The FDA has approved subcutaneous rituximab (Rituxan Hycela) for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia.

Adrienne A. Phillips, MD, discussed the subtypes of adult T-cell lymphoma/leukemia, the challenges with treating them, and what community oncologists need to know about these patient populations.